Navigation Links
Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology
Date:1/26/2012

SAN JOSE, Calif., Jan. 26, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, today announced the publication of an independent blinded study that examines the accuracy of its non-invasive prenatal test for the detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome). The study showed that the test, coupled with a proprietary algorithm to assess individualized risk for these trisomies, distinguished 100 percent of T21 and 98 percent of T18 cases, while correctly identifying 100 percent of the non-trisomic samples. The data appear online in the American Journal of Obstetrics & Gynecology at http://www.sciencedirect.com/science/article/pii/S0002937812000609?v=s5.

(Logo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO )

"This constitutes a major breakthrough in the non-invasive detection of the two most common trisomies," said Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom and lead author of the paper. "I am now certain that this test will become a universal screening tool for Trisomies 21 and 18, provided the cost becomes comparable to that of current methods of sonographic and biochemical testing."

The study, titled, "Chromosome-Selective Sequencing of Maternal Plasma Cell-Free DNA for First-Trimester Detection of Trisomy 21 and Trisomy 18" was independently conducted and supported by a grant from the Fetal Medicine Foundation. The study assessed the ability of Aria's highly multiplexed assay, known as Digital Analysis of Selected Regions (DANSR™), to detect T21 and T18 by using chromosome-selective sequencing and to calculate risk scores with the proprietary Fetal-fraction Optimized Risk of Trisomy Evaluation (FORTE™) algorithm in 400 pregnant women at 11 to 13 weeks gestation. In addition to demonstrating the accuracy of Aria's technology, researchers reported that chromosome-selective sequencing requires 10 times less DNA sequencing than massively parallel shotgun sequencing (MPSS) approaches.

"This study provides firm support that Aria's technology has the potential to transform prenatal trisomy testing. Current prenatal testing involves a myriad of options that are confusing and either lack accuracy or pose harm to the pregnant woman and fetus," said Ken Song, chief executive officer of Aria Diagnostics. "We are developing a test that can greatly simplify the standard of care for pregnant women and give providers and patients confidence as a result of our highly accurate results."

About Aria Diagnostics (formerly Tandem Diagnostics)

Aria Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Aria is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Aria's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariadx.com.


'/>"/>
SOURCE Aria Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
2. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
3. Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease
4. Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
5. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
6. Integware Announces Systems Integrator Agreement With Siemens PLM Software
7. Millennium Research Institute Announces 2012 Educational Initiatives
8. Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
9. Jazz Pharmaceuticals plc Announces New Executive Appointments
10. BD Announces Webcast of Annual Meeting of Shareholders
11. Codexis Announces CFO Departure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... on the development of novel therapies for metabolic ... Food and Drug Administration (FDA) has granted orphan ... X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a novel, orally ... regulates the expression of genes believed to be ...
(Date:12/6/2016)... 2016 Breast Pump Market size is estimated ... by Global Market Insights, Inc. Continue Reading ... ... , , ... women employment rates and rising consumer awareness regarding importance of breast feeding will ...
(Date:12/6/2016)... , Dec. 6, 2016 In this ... reason to be hopeful.  A special kind of sunglasses, ... less anxious life. Photo - ... Robert Buck, the psychotherapist who developed and patented ... approach to overcoming anxiety and worry.  "Anxiety doesn,t ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... Why does the prevalence of obesity continue to ... includes a fresh look into the cause of obesity in his new book “Body ... the knowledge needed to lead a healthy life. Proietto said understanding the regulation of ...
(Date:12/6/2016)... ... ... It can be argued that people these days spend as much time searching ... their human friends and family. As pets have assumed a bigger role in ... pet products has also increased. , For this reason, America’s Pet Health ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral ... of Distinction, recognizing the organization as a top behavioral service provider in the ... of clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
Breaking Medicine News(10 mins):